NuCana plc: NuCana Presents Positive Data on NUC-3373 at the 34th EORTC-NCI-AACR Annual Meeting 2022
NUC-3373 Potentiates Immunogenic Activity in Lung Cancer Cells Pembrolizumab Activity Increased by NUC-3373 in Lung Cancer Cells NuCana has Initiated the NuTide:303 Study of NUC-3373 in Combination
Comunidad Autonoma De Cataluna Hughs Griffith Marion Janic Chris Brinzey Company Annual Report On Form Exchange Commission
Source: finanznachrichten.de